Logo - International Journal of Pharmaceutical Compounding

Compounding with Biotechnology Products, Part 1: General Considerations

Author(s):  Allen Loyd V Jr

Issue:  Sep/Oct 2022 - Volume 26, Number 5
View All Articles in Issue

Abstract:  Biotechnology drugs involve any technique that uses living organisms in their production or modification. These biotechnology drugs are prepared using different techniques such as recombinant DNA technology monoclonal antibody technologies along with tissue cultures living cells and cell enzymes to make specific products. These new pharmaceuticals are utilized in the diagnosis treatment and prevention of disease but, because of the risk of clinically important and unusual and potentially harmful adverse effects produced, these agents require increased safety surveillance, and it is very important for pharmacists to participate in any adverse event reporting and monitoring program for these new products. The first biotechnology pharmaceuticals are proteins, but, eventually, an ever-increasing number of smaller molecules may be discovered through the previously mentioned methods and may become a mainstay in new pharmaceutical research and development in producing new drug products. Pharmacists involved in compounding must be aware of not only the biotechnology agent itself but especially of all of the different excipients that are required in order to produce a stable and safe preparation for patient use. Compounding involving these formulations should involve the simplest procedures and formulations as possible, maintaining sterility throughout the entire process. It is important to maintain a drug’s biologic activity up to the point of administration to the patient, and the pharmacist can assist in explaining the various factors involved in storage preparation and administration of the drugs to the patient. In the next issue of this two-part series, we will look at the formulations for a number of commercially available biotechnology products and the purpose of each of the ingredients and any uniqueness about their formulations.

Related Keywords: Loyd V. Allen Jr., PhD, RPh, biotechnology drugs, recombinant DNA technology, monoclonal antibody technology, tissue cultures, living cells, cell enzymes, adverse events, drug safety, biosimilars, follow-on biologics, biologic agents, polymerase chain reaction, PCR, gene therapy, nucleotide blockage, antisense nucleic acids, rDNA, protein drugs, stabilizers, filter loss, container sorption, protein structure, isoelectric point, molecular weight, solubility, stability, quality control, agitation, tissue penetration, absorption, immune reaction, drug delivery, nanoparticles, liposomes, targeted delivery, polymer-drug conjugates, pegylation, polyethylene glycol, encapsulation, nanomedicine, diagnostic products, patient education, chelating agents, antioxidants, preservatives, tonicity

Related Categories: STABILITIES, COMPATIBILITIES, TECHNOLOGY, QUALITY CONTROL, PATIENT EDUCATION, ADVERSE DRUG EVENTS, PROFESSIONAL ISSUES

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=5111

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products